Gallen Triana-Baltzer et al.
Alzheimer's & dementia (Amsterdam, Netherlands), 13(1), e12204-e12204 (2021-06-08)
Diagnosis of Alzheimer's disease (AD) based on amyloid beta (A), pathologic tau (T), and neurodegeneration (N) biomarkers in peripheral fluids promises to accelerate clinical trials and intercept disease earlier. Qualification of a Simoa plasma p217+tau assay was performed, followed by